Luye Pharma’s Biosimilar LY06006/BA6101 Approved for Osteoporosis Treatment
China-based Luye Pharma Group (HKG: 2186) has announced that it has received market approval from...
Drug
Lundbeck’s Eptinezumab Launches in Boao Lecheng for Migraine Treatment
Lundbeck’s (FRA: LDBB) Eptinezumab has been launched in the Boao Lecheng International Medical Tourism Zone,...
RemeGen’s Telitacicept Set for Breakthrough Therapy Designation in Myasthenia Gravis
The Center for Drug Evaluation (CDE) website indicates that China-based RemeGen Co., Ltd’s (HKG: 9995,...
CStone’s PD-L1 Inhibitor Sugemalimab Achieves Primary Endpoint in Gastric Cancer Study
China-based CStone Pharmaceuticals (HKG: 2616) has announced that its GEMSTONE-303 study for the programmed death-ligand...
BeiGene’s Brukinsa Receives Marketing Approval in Brazil
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that it has...
Fujian Cosunter Receives Multiple Patents for Cancer and Hepatitis Drugs
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the receipt of multiple patents...
Sinocelltech’s SCTV01E Vaccine Receives NMPA Approval for Phase II Study
China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received approval from the...
3SBio’s Thrombopoietin Study in Pediatric ITP Reaches Primary Endpoint
China-based 3SBio Inc. (HKG: 1530) has announced that its multi-center, randomized, double-blind, placebo-controlled study assessing...
LianBio Initiates Phase I Study of SHP2 Inhibitor BBP-398 in China
Sino-US biotech LianBio has announced the first patient dosing in a Phase I clinical study...
Ascentage Pharma Gains CDE Approval for Phase I Study of APG-5918
Suzhou-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the Center...
3SBio Receives NMPA Review for Pediatric ITP Thrombopoietin Filing
China-based 3SBio Inc. (HKG: 1530) has announced that the National Medical Products Administration (NMPA) has...
Betta Pharmaceuticals’ BPI-D0316 Shows Promise in Phase II/III Lung Cancer Study
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced the summary report of a Phase...
Haisco’s HSK16149 Accepted for Review by NMPA for Diabetic Neuropathic Pain
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that a market approval filing...
Liaoning Chengda’s ACYW135 Meningococcal Vaccine Receives NMPA Clearance
China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) has announced that it has received clinical...
Zhaoke Ophthalmology Enrolls First Patients for ZKY001 in Phase II Trials
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...
MicuRx Pharmaceuticals Doses First Patient in China for MRX-8 Trial
Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals (SHA: 688373) has announced the first patient dosing in...
Zhifei Bio Initiates Global Study for Omicron-Delta COVID-19 Vaccine in Uzbekistan
China-based Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd has announced the initiation of a global clinical study...
Cyramza Prescribed in China for Advanced Gastric Cancer
Cyramza (ramucirumab) was first prescribed on November 6, 2022, at the Zhongshan Hospital in Shanghai...
Merck’s Keytruda Receives 10th Indication Approval in China for TNBC
US-based Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab) has...